Menu
Not yet recruiting NCT06625801

IVUS CHIP UPP Registry

Observational Coronary Artery Disease Coronary Artery Disease Risk High Complex Coronary Artery Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: IVUS.
Who it may be relevant to
Registry conditions: Coronary Artery Disease, Coronary Artery Disease Risk High, Complex Coronary Artery Disease. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Intravascular Ultrasound Guidance for Complex High-risk Indicated Procedures in Underrepresented Patient Populations Registry

Overview

The IVUS CHIP UPP Registry is a prospective, observational, multicenter, single-arm registry. A total of 1010 patients with complex coronary lesions will be enrolled in up to 2 years, with at least 500 men and women. All patients will be treated with IVUS-guided PCI.

Detailed description

Objective is to describe in a United States population the clinical efficacy and safety of an IVUS-guided approach in patients who self-identify within a census-defined minority undergoing PCI of complex coronary lesions, as well as clinical outcomes up to 2 years.

Interventions

  • Device IVUS
    Intravascular Ultrasound

Primary outcome measures

  • Target-vessel failure (TVF) [Time frame: 1 year after enrollment]

Eligibility criteria

Inclusion criteria

  • The patient must be ≥18 years of age and self-identify within a US census-defined minority
  • Patients with an indication for PCI of at least one lesion satisfying any of the following criteria:
  • Angiographic heavy calcification
  • Ostial lesions
  • True bifurcation lesions involving side-branches \>2.5mm
  • Left main lesions
  • Chronic total occlusion
  • In-stent restenosis
  • Long-lesions (estimated stent length \> 28mm) OR Patient with an indication for PCI for any lesion and in need for elective mechanical circulatory support assisted PCI
  • Presenting with silent ischemia, stable angina, unstable angina or non-ST-elevation acute coronary syndrome (NSTE-ACS)
  • All lesions must be suitable for treatment with FDA-approved contemporary generation drug eluting stents or drug-coated balloons
  • The patient is willing and able to cooperate with registry procedures and follow-up until registry completion
  • Subject is able to confirm understanding of risks, benefits and treatment alternatives and he/she (or an authorized legal representative) provides informed consent prior to any protocol-related procedure, as approved by the appropriate IRB

Exclusion criteria

  • ST-elevation myocardial infarction or cardiogenic shock within prior 7 days
  • Known untreated severe valvular heart disease
  • Contraindication on the use of IVUS (i.e. extreme vessel tortuosity)
  • Requiring PCI in a diseased aorto-coronary bypass
  • Known contraindication or hypersensitivity to anticoagulants
  • Absolute contraindications or allergy that cannot be pre-medicated, to iodinated contrast or to antiplatelet drugs, including both aspirin and P2Y12 inhibitors
  • Non-cardiac co-morbidities with a life expectancy less than 1 year
  • A patients that is currently participating in a clinical trial that has not yet reached its primary endpoint cannot be included in this registry. A patient may only be enrolled in this registry once.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06625801 · ECRI-14-US

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗